Why Venture Capital Is Concentrating Wealth in Fewer AI-Driven Startups

When Capital Stays High But Deals Vanish

Global venture funding held its ground in Q2 2026, according to Crowdfund Insider — but look closer and the headline masks a troubling dynamic. Deal volume sank to a decade-low. That means larger checks funneling into fewer hands. Capital concentration, not broad-based recovery. The top of the market is feasting; early-stage founders are fighting over crumbs.

The split runs through every vertical. Rock Health data, as reported by HIT Consultant, pegs H1 2026 digital health funding at $7.4 billion — a rebound on paper. But a rebound for whom? Mega-rounds in AI-adjacent clinical tooling can mask shrinking seed activity beneath a single aggregated number. Investors aren't deploying broadly. They're buying concentrated positions in companies they believe can survive the next 18 months without a follow-on.

India tells a different story. Per ascendants.in, startup funding there dropped 18 percent year-over-year to $11.7 billion in FY26. No rescue round is coming. The domestic market is repricing in real time, and cross-border capital has grown pickier about where it parks dollars outside the US.

The Macro Picture: Fewer Bets, Bigger Bets

It's contracting in conviction. LPs still allocate to top-quartile managers. Those managers still write checks — but only when valuation multiples align with a defensible path to liquidity. Everyone else waits. Burn rates matter again. Cap tables are getting scrutinized the way they should have been in 2021.

The decade-low deal count is the signal. Elevated dollar volume is the noise. When money pools at the top while transaction counts crater, it tells you the market has decided most startups aren't worth the risk premium. That's not a funding winter. It's a funding triage.

What to Watch

For AI-ecosystem investors, the question is whether this concentration trend accelerates through H2 2026. If Q3 deal volume stays depressed while mega-rounds keep closing, the venture landscape effectively bifurcates: funded survivors and everyone else burning runway toward an unforgiving repricing event.

Keep an eye on secondary market activity as a leading indicator. When primary rounds slow but secondaries spike, founders and early employees are monetizing at discounted multiples — a signal that smart money sees the ceiling before the next round gets marked down.

The era of spray-and-pray is over. Capital is still flowing, but the funnel has narrowed to a needle.